Rajender R Aparasu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8287384/publications.pdf

Version: 2024-02-01

142 papers 3,391 citations

147801 31 h-index 51 g-index

143 all docs $\begin{array}{c} 143 \\ \text{docs citations} \end{array}$

143 times ranked 3776 citing authors

#	Article	IF	CITATIONS
1	Prescribing of disease modifying agents in older adults with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103308.	2.0	3
2	Risk of overactive bladder associated with cholinesterase inhibitors in dementia. Journal of the American Geriatrics Society, 2022, 70, 820-830.	2.6	1
3	FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Multiple Sclerosis and Related Disorders, 2022, 60, 103703.	2.0	1
4	Citicoline and COVID-19-Related Cognitive and Other Neurologic Complications. Brain Sciences, 2022, 12, 59.	2.3	11
5	Use of national databases and surveys to evaluate prescribing patterns and medication use. , 2022, , 527-539.		O
6	Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs and Aging, 2022, 39, 453-465.	2.7	4
7	Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Multiple Sclerosis and Related Disorders, 2022, 66, 104019.	2.0	2
8	Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. International Journal of Geriatric Psychiatry, 2021, 36, 684-696.	2.7	8
9	Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries. Journal of the American Medical Directors Association, 2021, 22, 1300-1306.	2.5	5
10	Opioid Prescribing Among Outpatients with Rheumatoid Arthritis. Pain Medicine, 2021, 22, 2224-2234.	1.9	4
11	Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder. Drugs and Aging, 2021, 38, 311-326.	2.7	1
12	Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. Drugs and Aging, 2021, 38, 493-502.	2.7	2
13	Comparative treatment effectiveness of oral fingolimod and conventional injectable diseaseâ€modifying agents in multiple sclerosis. Pharmacotherapy, 2021, 41, 440-450.	2.6	1
14	Chemoprotective effect of metformin against HR+/HER2- breast cancer among women with type-2 diabetes Journal of Clinical Oncology, 2021, 39, 10518-10518.	1.6	0
15	Application of machine learning in predicting hospital readmissions: a scoping review of the literature. BMC Medical Research Methodology, 2021, 21, 96.	3.1	46
16	Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia. Drugs and Aging, 2021, 38, 593-602.	2.7	5
17	Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Current Medical Research and Opinion, 2021, 37, 1303-1313.	1.9	3
18	National surveys to evaluate prescribing practices: Methodological considerations. Research in Social and Administrative Pharmacy, 2021 , , .	3.0	1

#	Article	IF	CITATIONS
19	Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Exploratory Research in Clinical and Social Pharmacy, 2021, 2, 100021.	1.0	0
20	The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US. PharmacoEconomics - Open, 2021, 5, 727-736.	1.8	4
21	Impact of geographic access to primary care providers on pediatric behavioral health screening. Preventive Medicine, 2021, 153, 106856.	3.4	4
22	Documentation of asthma control and severity in pediatrics: analysis of national office-based visits. Journal of Asthma, 2020, 57, 205-216.	1.7	9
23	Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. Research in Social and Administrative Pharmacy, 2020, 16, 329-335.	3.0	16
24	Racial/ethnic differences in treatment quality among youth with primary care providerâ€initiated versus mental health specialistâ€initiated care for major depressive disorders. Child and Adolescent Mental Health, 2020, 25, 28-35.	3.5	8
25	Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries. Advances in Therapy, 2020, 37, 3584-3605.	2.9	1
26	Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. Patient Preference and Adherence, 2020, Volume 14, 2187-2199.	1.8	12
27	Anticholinergic medications and risk of dementia in older adults: Where are we now?. Expert Opinion on Drug Safety, 2020, 19, 1251-1267.	2.4	9
28	Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. Journal of Managed Care & Eamp; Specialty Pharmacy, 2020, 26, 741-749.	0.9	7
29	Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Multiple Sclerosis and Related Disorders, 2020, 45, 102334.	2.0	5
30	Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Research in Social and Administrative Pharmacy, 2020, 16, 1670-1676.	3.0	7
31	Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. Journal of General Internal Medicine, 2020, 35, 2084-2093.	2.6	13
32	<p>Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression</p> . Drug, Healthcare and Patient Safety, 2020, Volume 12, 23-30.	2.5	8
33	Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. American Journal of Geriatric Psychiatry, 2020, 28, 1079-1088.	1.2	5
34	Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Research in Social and Administrative Pharmacy, 2019, 15, 395-403.	3.0	15
35	Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease. Journal of Psychiatric Research, 2019, 117, 116-121.	3.1	8
36	Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Research, 2019, 276, 151-159.	3.3	9

#	Article	IF	Citations
37	The association between geographic access to providers and the treatment quality of pediatric depression. Journal of Affective Disorders, 2019, 253, 162-170.	4.1	11
38	Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 29-38.	0.9	6
39	The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer, 2019, 125, 1155-1162.	4.1	72
40	Asthma Medication Prescribing Practices in Pediatric Office Visits. Clinical Pediatrics, 2019, 58, 395-405.	0.8	1
41	Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD. Journal of Attention Disorders, 2019, 23, 163-172.	2.6	7
42	Consideration of Aggressive and Strategic Approaches to Address Declining Enrollment in US Pharmacy Schools. American Journal of Pharmaceutical Education, 2019, 83, 6959.	2.1	26
43	FRAX tool underestimates the risk of osteoporotic fractures in mental disorders. Evidence-Based Mental Health, 2018, 21, 80-80.	4.5	O
44	Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. Journal of Affective Disorders, 2018, 235, 155-161.	4.1	5
45	Atypical antipsychotic prescribing in elderly patients with depression. Research in Social and Administrative Pharmacy, 2018, 14, 645-652.	3.0	6
46	Outcomes associated with <i>Clostridium difficile</i> infection in patients with chronic liver disease. Epidemiology and Infection, 2018, 146, 1101-1105.	2.1	18
47	Acetylcholinesterase Inhibitors: Start Low or Risk Going Slow?. Journal of the American Geriatrics Society, 2018, 66, 1663-1664.	2.6	0
48	The impact of concomitant use of tyrosine kinase inhibitors and proton pump inhibitors on survival in older adults with cancer Journal of Clinical Oncology, 2018, 36, e18732-e18732.	1.6	0
49	Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Research in Social and Administrative Pharmacy, 2017, 13, 358-363.	3.0	45
50	Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD. Psychiatric Services, 2017, 68, 681-688.	2.0	25
51	Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy, 2017, 37, 287-296.	2.6	9
52	Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 349-358.	1.3	13
53	The Impact of Pharmacotherapy on Substance Use in Adolescents With Attention-Deficit/Hyperactivity Disorder: Variations Across Subtypes. Substance Use and Misuse, 2017, 52, 1266-1274.	1.4	8
54	Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression. Drugs and Aging, 2017, 34, 691-700.	2.7	21

#	Article	IF	CITATIONS
55	Discharge medication complexity and 30-day heart failure readmissions. Research in Social and Administrative Pharmacy, 2017, 13, 857-863.	3.0	25
56	Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. Journal of the American Geriatrics Society, 2016, 64, 1492-1497.	2.6	28
57	Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case–Control Study. Journal of the American Geriatrics Society, 2016, 64, 394-400.	2.6	41
58	Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 395-404.	1.9	8
59	Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Drugs and Aging, 2016, 33, 755-763.	2.7	11
60	Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression. Pharmacotherapy, 2016, 36, 38-48.	2.6	7
61	Functional Status of Elderly Nursing Home Residents With Parkinson's Disease. Journal of Parkinson's Disease, 2016, 6, 617-624.	2.8	7
62	Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. Journal of Comparative Effectiveness Research, 2016, 5, 461-473.	1.4	6
63	Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. American Journal of Geriatric Psychiatry, 2016, 24, 485-495.	1.2	24
64	Quality of life of patients with Parkinson's disease and neurodegenerative dementia: A nationally representative study. Research in Social and Administrative Pharmacy, 2016, 12, 604-613.	3.0	20
65	Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. Annals of Pharmacotherapy, 2016, 50, 96-105.	1.9	3
66	Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 678-686.	1.9	10
67	Potentially inappropriate anticholinergic medication use in older adults with dementia. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 603-612.	1.5	24
68	Anticholinergic drugs and health-related quality of life in older adults with dementia. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 282-287.	1.5	10
69	Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia inÂPatients with Type 2 Diabetes andÂHypertension. Journal of Alzheimer's Disease, 2015, 49, 423-432.	2.6	23
70	Predictors of Concomitant Use of Antipsychotics and Stimulants and Its Impact on Stimulant Persistence in Pediatric Attention Deficit Hyperactivity Disorder. Journal of Managed Care & Decialty Pharmacy, 2015, 21, 486-498.	0.9	8
71	Concurrent Use of Stimulants and Second-Generation Antipsychotics Among Children With ADHD Enrolled in Medicaid. Psychiatric Services, 2015, 66, 404-410.	2.0	22
72	Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors. Psychiatric Services, 2015, 66, 1333-1340.	2.0	18

#	Article	IF	CITATIONS
73	Antipsychotic Use and Risk of Nursing Home Admission Among Dual-Eligible Medicare Beneficiaries: A Propensity-Matched Study. Drugs - Real World Outcomes, 2015, 2, 61-71.	1.6	O
74	Potentially Inappropriate Anticholinergic Medication Use in Community-Dwelling Older Adults: A National Cross-Sectional Study. Drugs and Aging, 2015, 32, 379-389.	2.7	36
75	Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. Drugs and Aging, 2015, 32, 743-754.	2.7	11
76	Which riskâ€adjustment index performs better in predicting 30â€day mortality? A systematic review and metaâ€analysis. Journal of Evaluation in Clinical Practice, 2015, 21, 292-299.	1.8	10
77	Use of narcotic analgesics associated with increased falls and fractures in elderly patients with osteoarthritis. Evidence-Based Medicine, 2014, 19, 37-38.	0.6	5
78	Risk of Hospitalization and Use of First-Versus Second-Generation Antipsychotics Among Nursing Home Residents. Psychiatric Services, 2014, 65, 781-788.	2.0	11
79	A Comparison of Supervised Machine Learning Techniques for Predicting Short-Term In-Hospital Length of Stay among Diabetic Patients. , 2014, , .		44
80	Risk of Manic Switch Associated with Antidepressant Therapy in Pediatric Bipolar Depression. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 551-561.	1.3	14
81	Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. Pharmacoepidemiology and Drug Safety, 2014, 23, 299-308.	1.9	10
82	Prevalence and Determinants of Anticholinergic Medication Use in Elderly Dementia Patients. Drugs and Aging, 2013, 30, 837-844.	2.7	42
83	The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. Journal of Affective Disorders, 2013, 150, 424-429.	4.1	12
84	Prevalence of anticholinergic use among older home health patients. Journal of Clinical Nursing, 2013, 22, 285-288.	3.0	8
85	Application of the nonlinear Blinder-Oaxaca decomposition to study racial/ethnic disparities in antiobesity medication use in the United States. Research in Social and Administrative Pharmacy, 2013, 9, 13-26.	3.0	17
86	Risk of Pneumonia in Elderly Nursing Home Residents Using Typical Versus Atypical Antipsychotics. Annals of Pharmacotherapy, 2013, 47, 464-474.	1.9	21
87	Pilot of a patient-centered pharmacy practice model. American Journal of Health-System Pharmacy, 2012, 69, 1860-1861.	1.0	1
88	Datapoints: Psychotropic Drug Use Among Elderly Patients in Home Care in the United States. Psychiatric Services, 2012, 63, 6-6.	2.0	2
89	Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. Journal of Comparative Effectiveness Research, 2012, 1, 195-206.	1.4	8
90	Persistence of Stimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 139-148.	1.3	36

#	Article	IF	CITATIONS
91	Risk of Death in Dual-eligible Nursing Home Residents Using Typical or Atypical Antipsychotic Agents. Medical Care, 2012, 50, 961-969.	2.4	26
92	Prevalence and predictors of human papillomavirus vaccination in adolescent girls. Journal of the American Pharmacists Association: JAPhA, 2012, 52, 52-58.	1.5	8
93	Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimer's and Dementia, 2012, 8, 437-444.	0.8	61
94	Risk of Falls and Fractures in Older Adults Using Atypical Antipsychotic Agents: A Propensity Score–Adjusted, Retrospective Cohort Study. American Journal of Geriatric Pharmacotherapy, 2012, 10, 83-94.	3.0	33
95	Comparative Risk of Cerebrovascular Adverse Events in Community-Dwelling Older Adults using Risperidone, Olanzapine and Quetiapine. Drugs and Aging, 2012, 29, 807-817.	2.7	24
96	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiology and Drug Safety, 2012, 21, 233-240.	1.9	15
97	Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: A multiple-propensity analysis. Research in Social and Administrative Pharmacy, 2012, 8, 145-156.	3.0	7
98	Prevalence and Predictors of Antidepressant Prescribing in Nursing Home Residents in the United States. American Journal of Geriatric Pharmacotherapy, 2011, 9, 109-119.	3.0	50
99	Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents. American Journal of Geriatric Pharmacotherapy, 2011, 9, 120-132.	3.0	20
100	Prevalence and Predictors of Anticholinergic Agents in Elderly Outpatients with Dementia. American Journal of Geriatric Pharmacotherapy, 2011, 9, 434-441.	3.0	32
101	Risk factors for dementia in patients over 65 with diabetes. International Journal of Geriatric Psychiatry, 2011, 26, 749-757.	2.7	49
102	The Definition and Prevalence of Pediatric Psychotropic Polypharmacy. Psychiatric Services, 2011, 62, 1450-1455.	2.0	34
103	Off-Label Use of Second-Generation Antipsychotic Agents Among Elderly Nursing Home Residents. Psychiatric Services, 2010, 61, 130-136.	2.0	56
104	Risk of Cerebrovascular Adverse Events in Older Adults Using Antipsychotic Agents. Journal of Clinical Psychiatry, 2010, 71, 689-698.	2.2	23
105	Health care consequences of black-box warnings for antidepressants in the United States and Canada. Research in Social and Administrative Pharmacy, 2010, 6, 78-84.	3.0	5
106	Extent of functional impairment in children and adolescents with depression. Current Medical Research and Opinion, 2010, 26, 2057-2064.	1.9	25
107	Prevalence and Predictors of Anticholinergic Medication Use in Elderly Nursing Home Residents with Dementia. Drugs and Aging, 2010, 27, 987-997.	2.7	48
108	Risk of Falls and Fractures in Older Adults Using Antipsychotic Agents. Drugs and Aging, 2010, 27, 815-829.	2.7	29

#	Article	IF	CITATIONS
109	Concomitant antipsychotic prescribing in US outpatient settings. Research in Social and Administrative Pharmacy, 2009, 5, 234-241.	3.0	18
110	Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US. Drugs and Aging, 2009, 26, 483-492.	2.7	97
111	Unmet prescription medication need in U.S. children. Journal of the American Pharmacists Association: JAPhA, 2009, 49, 769-776.	1.5	9
112	Hypertension management in outpatient visits by diabetic patients. Research in Social and Administrative Pharmacy, 2008, 4, 284-291.	3.0	9
113	Antipsychotic drug use among elderly nursing home residents in the United States. American Journal of Geriatric Pharmacotherapy, 2008, 6, 187-197.	3.0	93
114	Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. American Journal of Geriatric Pharmacotherapy, 2008, 6, 198-204.	3.0	30
115	Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996–2004. Current Medical Research and Opinion, 2008, 24, 709-716.	1.9	22
116	The Impact of Medicare Part D on Psychotropic Utilization and Financial Burden for Community-Based Seniors. Psychiatric Services, 2008, 59, 1191-1197.	2.0	27
117	Healthcare Outcomes Associated with Beers' Criteria: A Systematic Review. Annals of Pharmacotherapy, 2007, 41, 438-448.	1.9	239
118	Pharmacotherapy with Atomoxetine for US Children and Adolescents. Annals of Clinical Psychiatry, 2007, 19, 175-180.	0.6	6
119	Datapoints: Antipsychotic Utilization and Expenditure Trends Among Elderly Persons. Psychiatric Services, 2007, 58, 1400-1400.	2.0	7
120	Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003–2004. Current Medical Research and Opinion, 2007, 23, 49-56.	1.9	57
121	Clinically important potential drug-drug interactions in outpatient settings. Research in Social and Administrative Pharmacy, 2007, 3, 426-437.	3.0	50
122	Antipsychotic Use and Expenditure in the United States. Psychiatric Services, 2006, 57, 1693-1693.	2.0	14
123	Interaction Between Selective Serotonin Reuptake Inhibitors and Nonsteroidal Antiinflammatory Drugs: Review of the Literature. Pharmacotherapy, 2006, 26, 1307-1313.	2.6	61
124	Polypharmacy trends in office visits by the elderly in the United States, 1990 and 2000. Research in Social and Administrative Pharmacy, 2005, 1, 446-459.	3.0	55
125	U.S. National Trends in the Use of Antipsychotics During Office Visits, 1998–2002. Annals of Clinical Psychiatry, 2005, 17, 147-152.	0.6	48
126	Datapoints: Antipsychotic Prescribing Trends Among Youths, 1997-2002. Psychiatric Services, 2005, 56, 904-904.	2.0	21

#	Article	IF	Citations
127	Prevalence, correlates, and associated outcomes of potentially inappropriate psychotropic use in the community-dwelling elderly. American Journal of Geriatric Pharmacotherapy, 2004, 2, 102-111.	3.0	64
128	Psychotropic Prescription Use by Community-Dwelling Elderly in the United States. Journal of the American Geriatrics Society, 2003, 51, 671-677.	2.6	121
129	Psychotropic Medication Expenditures for Community-Dwelling Elderly Persons. Psychiatric Services, 2003, 54, 739-742.	2.0	5
130	Prescribing of Psychotropics in the Elderly. CNS Drugs, 2002, 16, 99-109.	5.9	62
131	Visits to Hospital Outpatient Departments in the United States Due to Adverse Effects of Medications. Hospital Pharmacy, 2000, 35, 825-831.	1.0	7
132	Inappropriate Prescribing for the Elderly: Beers Criteria-Based Review. Annals of Pharmacotherapy, 2000, 34, 338-346.	1.9	208
133	Prescribing Potentially Inappropriate Psychotropic Medications to the Ambulatory Elderly. Archives of Internal Medicine, 2000, 160, 2825.	3.8	106
134	Attitudinal Dimensions that Determine Pharmacists' Decisions to Support DTCA of Prescription Medication. Drug Information Journal, 2000, 34, 103-114.	0.5	14
135	Inappropriate prescribing for elderly outpatients. American Journal of Health-System Pharmacy, 1999, 56, 433-439.	1.0	76
136	Opioid-Induced Emesis Among Hospitalized Nonsurgical Patients. Journal of Pain and Symptom Management, 1999, 18, 280-288.	1.2	54
137	Visits to Office-Based Physicians in the United States for Medication-Related Morbidity. Journal of the American Pharmacists Association, 1999, 39, 332-337.	0.5	14
138	Pschotropic prescribing for the elderly in office-based practice. Clinical Therapeutics, 1998, 20, 603-616.	2.5	30
139	Drug-related-injury visits to hospital emergency departments. American Journal of Health-System Pharmacy, 1998, 55, 1158-1161.	1.0	15
140	Inappropriate Medication Prescribing for the Elderly by Office-Based Physicians. Annals of Pharmacotherapy, 1997, 31, 823-829.	1.9	109
141	Path model for analyzing factors associated with salaries of Louisiana hospital pharmacists. American Journal of Health-System Pharmacy, 1996, 53, 1706-1708.	1.0	1
142	Pharmacy Education In Indonesia. Pharmacy Education, 0, 21, 432-442.	0.6	3